

Green Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Reversed-phase Liquid Chromatography with Mixed Micellar Mobile Phases**
2 **of Brij-35 and Sodium Dodecyl Sulphate:**
3 **A Method for the Analysis of Basic Compounds**

4 M.J. Ruiz-Angel, E. Peris-García and M.C. García-Alvarez-Coque*

5
6
7 *Departament de Química Analítica, Universitat de València, c/Dr. Moliner 50, Burjassot*
8 *(Spain)*

9 *E-mail: celia.garcia@uv.es; Tel. +34 96354 4005*

10

11 Micellar liquid chromatography (MLC) is a reversed-phase liquid chromatographic
12 (RPLC) mode, which uses a surfactant as modifier, with significant changes in
13 retention and selectivity with regard to the classical RPLC mode that employs
14 mixtures of water and organic solvent. The anionic sodium dodecyl sulphate (SDS) is
15 the most usual surfactant in MLC, but it also requires the addition of an organic
16 solvent to decrease the retention times and increase the efficiency. Particularly,
17 positively charged basic compounds are strongly retained by the stationary phase
18 modified by adsorption of SDS monomers and require the addition of a strong
19 solvent, such as propanol or pentanol. The non-ionic surfactant Brij-35 is much less
20 common in MLC, but has the interesting feature of reducing the stationary phase
21 polarity which remains neutral. This decreases the retention significantly and can
22 eliminate the need of organic solvent, giving rise to successful “green” RPLC
23 procedures. However, the retention of polar compounds may be too short if these do
24 not exhibit specific interactions with the non-ionic surfactant. In this work, MLC with
25 Brij-35 and mixtures of Brij-35 and SDS without organic solvent is investigated for the
26 analysis of basic compounds. The research has been carried out with tricyclic
27 antidepressants (TCAs) and β -blockers, which are compounds of pharmaceutical
28 interest with different polarity. The chromatographic performance in the mixed
29 micellar system is examined in terms of retention behaviour and peak profiles, and
30 compared with the performance achieved with MLC systems containing a single
31 surfactant. In the mixed micellar system, the analysis of β -blockers of diverse polarity
32 is carried out with good resolution and adequate analysis time. For TCAs, mobile
33 phases with only Brij-35 are preferable.

34

35

36

37

38 *Keywords:* Micellar liquid chromatography; Brij-35; Sodium dodecyl sulphate; Mixed
39 micellar system; Basic compounds

40

41 Introduction

42 The idea of adding a surfactant to the mobile phase in reversed-phase liquid chromatography
43 (RPLC) is a practice that has been explored over the three last decades, with significantly
44 different results in the analysis of compounds of diverse nature with respect to those obtained
45 in classical RPLC that employs mixtures of water and organic solvent.¹⁻³ Surfactant
46 monomers are adsorbed on the alkyl-bonded chains of the stationary phase (usually C8 or
47 C18) through hydrophobic interactions, modifying its nature. This creates a neutral or charged
48 double layer (depending on the nature of the adsorbed surfactant), which interacts with
49 solutes. For stationary phases modified with a charged surfactant, a dynamic ion-exchanger is
50 yielded. Moreover, above the critical micelle concentration, surfactant monomers in the
51 mobile phase aggregate to form small clusters or micelles that also interact with solutes. The
52 formation of micelles has given rise to the most accepted name for this chromatographic
53 mode: micellar liquid chromatography (MLC). However, the main changes in the observed
54 chromatographic performance are due to the adsorption of surfactant monomers on the
55 stationary phase. An attractive feature of MLC is the significant reduction in the amount of
56 organic solvent with respect to the classical RPLC. Another fascinating feature is the
57 capability of micelles of some surfactants to solubilize proteins that has been effectively
58 exploited for the direct injection of untreated biological fluids onto RPLC columns, avoiding
59 previous extraction steps with organic solvents.^{4,5} For this reason, MLC is considered a
60 “green” RPLC mode.⁶

61 Although several surfactants of diverse nature can be used in MLC, the anionic sodium
62 dodecyl sulphate (SDS) has been selected in most reports.^{1,2} The frequent use of SDS has
63 somehow relegated the research on the potential of other surfactants as modifiers, such as the
64 non-ionic surfactants. One of such surfactants is polyoxyethylene(23)lauryl ether
65 ((C₂H₄O)₂₃C₁₂H₂₅OH), commercially known as Brij-35, which has been explored by a few

66 authors as an alternative to SDS with satisfactory results.⁷⁻¹⁷ Brij-35 has been also reported as
67 an ideal modifier in quantitative structure-activity relationship studies (QSARs) in RPLC, due
68 to its capability to mimic biopartitioning processes.^{18,19}

69 When RPLC columns are used with mixtures of water and organic solvent, solute
70 retention is mainly based on the hydrophobic interactions with the alkyl-bonded layer of the
71 stationary phase, together with the solvating power of the organic solvent in the mobile phase.
72 When cationic compounds are analysed, additional ion-exchange interaction with residual
73 anionic silanols on the silica packing are established. These interactions are also characterised
74 by slow kinetics, which results in broad and skewed peaks.^{20,21} Mobile phases containing SDS
75 have demonstrated to minimise the interaction of cationic solutes with the residual silanols:
76 the long hydrophobic chain of SDS monomers covers the stationary phase with the sulphate
77 group oriented outside, resulting in a negatively charged stationary phase.²² This enhances
78 remarkably the efficiency and peak symmetry of basic compounds, such as tricyclic
79 antidepressants (TCAs) and β -blockers.

80 However, due to the attraction of the cationic basic compounds to the anionic SDS
81 modified stationary phase their retention increases significantly. This forces the addition of a
82 relatively high amount of acetonitrile or propanol to elute most β -blockers,^{23,24} and pentanol is
83 required to elute TCAs.²⁵ If Brij-35 is used instead of SDS, its monomers are adsorbed on the
84 stationary phase with the hydrophilic polar end of the molecule oriented away from the
85 surface. This increases the polarity of the stationary phase without providing a net charge,
86 which allows compounds of low or intermediate polarity be eluted without the addition of
87 organic solvent.^{26,27} However, polar compounds as most β -blockers, which do not establish
88 specific interactions with Brij-35, are not retained.

89 In this work, it is shown that a solution for the described limitations of mobile phases
90 containing a single surfactant (Brij-35 or SDS), in the RPLC analysis of β -blockers, is the use

91 of mobile phases that include both surfactants, so that the favourable characteristics of each
92 surfactant are combined. These mixed systems have been investigated along the last decades
93 outside the field of chromatography.²⁸ Thus, it is known that when an anionic surfactant (such
94 as SDS) and a non-ionic surfactant (such as Brij-35) are mixed in aqueous solution, their tails
95 establish hydrophobic interactions, and their head groups ion-dipole and hydrophilic
96 interactions, giving rise to the formation of mixed micelles. Systems containing mixed
97 surfactants have been scarcely used in MLC,^{29–32} being the combination of Brij-35 and SDS
98 the most common. The mixed systems may result in improvements in the chromatographic
99 performance with respect to the use of mobile phases containing a single surfactant.

100 The capability of mobile phases containing exclusively Brij-35 or the combination of
101 Brij-35 and SDS to elute basic compounds, specifically TCAs and β -blockers, is here studied.
102 The results are analysed in terms of retention, peak profiles, selectivity and resolution. Since
103 there is no organic solvent in the mobile phase, the greenness of the method is increased with
104 respect to classical RPLC or MLC with hybrid mobile phases of SDS and organic solvent.
105 Another important advantage is the biodegradable character of the reagents used in the mobile
106 phase: SDS is a fatty alcohol sulphate that is aerobically degraded,³³ and Brij-35 is a
107 derivative of fatty alcohol ethoxylate, developed as an eco-friendly alternative to alkyl phenol
108 ethoxylates.³⁴ It is shown how their combined use gives rise to a successful “green” RPLC
109 separation of β -blockers.

110

111 2. Experimental

112 2.1. Reagents

113 The probe compounds were seven TCAs (doxepin, amitriptyline, clomipramine,
114 imipramine, maprotiline, nortriptyline, and trimipramine) and six β -blockers (alprenolol,
115 atenolol, celiprolol, metoprolol, oxprenolol, and propranolol), all from Sigma (St. Louis, MO,
116 USA). All these compounds are basic ($pK_a = 9-10$), which means that at the working pH of
117 the mobile phase (~ 3) they are positively charged. Most experiments were carried out with the
118 seven TCAs and the two most hydrophobic β -blockers (propranolol and alprenolol), all of them
119 sufficiently retained with Brij-35. As will be commented below, atenolol, celiprolol,
120 metoprolol and oxprenolol eluted close to the dead time with Brij-35.

121 Stock solutions of 100 $\mu\text{g/mL}$ of the drugs were prepared in a small amount of ethanol
122 with the aid of an Elmas 15h ultrasonic bath from Elmasonic (Singen, Germany), and diluted
123 with water. These solutions were stable during at least two months at 4°C and were diluted
124 before injection with an aqueous solution of 0.02 M Brij-35 (Fluka, Buchs, Switzerland) up to
125 a final concentration of 20 $\mu\text{g/mL}$. Uracil (Acros Organics, Geel, Belgium) was used as dead
126 time marker.

127 Mobile phases containing Brij-35 or a mixture of Brij-35 and SDS (99% purity, Merck,
128 Darmstad, Germany) were prepared at different concentrations, buffered at pH ~ 3 with
129 0.01 M sodium dihydrogen phosphate (Panreac, Barcelona, Spain) and HCl, to reduce the
130 amount of free silanols in the column. The solutions of the probe compounds and mobile
131 phases were filtered through 0.45 μm Nylon membranes (Micron Separations, Westboro, MA,
132 USA). Nanopure water (Barnstead, Sybron, Boston, MA, USA) was used throughout.

133

134 2.2. Chromatographic system and column

135 An Agilent chromatograph (Waldbronn, Germany), equipped with a quaternary pump
136 (Series 1260), an autosampler (Series 1200), a thermostated column compartment (Series
137 1100) set at 25°C, a diode array detector, and an HPChemStation (Agilent, B.02.01) for data
138 acquisition, was used. TCAs and β -blockers were monitored at 254 and 225 nm, respectively.

139 The chromatographic column was a Zorbax Eclipse C18 (Agilent) with the following
140 characteristics: 150 mm \times 4.6 mm i.d., 5 μ m particle size, 10% carbon load, 180 m²/g surface
141 area, and 80 Å pore size, which was connected to a similar 30 mm pre-column for protection.
142 The flow-rate was 1 mL/min. Duplicate injections were made using an injection volume of
143 20 μ L. The mobile phases were recycled between runs and also during the analysis (as long as
144 a small number of injections was made) to reduce the consumption of reagents. This increases
145 the sustainability of the procedure. The chromatographic system was periodically rinsed with
146 water and methanol (around 20 mL) to remove the surfactant from the stationary phase.

147

148 2.3. Experimental design

149 Based on previous experience,²⁴⁻²⁶ two mobile phases containing either 0.02 M Brij-35 or
150 0.15 M SDS were selected as references. SDS was added to the 0.02 M Brij-35 solution at the
151 following concentrations: 0.02, 0.04, 0.08, 0.12, and 0.15 M. Similarly, Brij-35 was added to
152 the 0.15 M SDS solution at the concentrations: 0.01, 0.02, 0.03, 0.04, and 0.05 M (the latter
153 concentration being close to the solubility of Brij-35 in water). The minimal and maximal
154 concentrations of the surfactants in the mobile phase were selected to achieve enough
155 retention for the most polar compounds, and not excessive retention for the most apolar.

156

157 3. Results and discussion

158 3.1. Retention capability of the mixed Brij-35/SDS micellar systems

159 The modified stationary phase coated by polyoxyethylene chains of Brij-35 is
160 significantly more polar than the original C18 bonded phase. This reduces the retention times
161 of the analysed compounds, if no specific interactions with the adsorbed surfactant are
162 established, such as hydrogen-bonding between the hydroxyl groups in the surfactant and
163 phenolic compounds.²⁷ The micellised surfactant in the mobile phase also changes the elution
164 strength and selectivity (relative retention). Micelles formed by Brij-35 contain a dodecyl
165 apolar core (similarly to SDS) and a relatively polar surface formed by oxyethylene chains,
166 which interact with the solutes in the mobile phase.

167 Surfactant monomers of SDS and Brij-35 compete for adsorption sites on the stationary
168 phase. The long hydrophobic chain of SDS monomers is inserted into the alkyl-bonded layer
169 (similarly to Brij-35), with the sulphate group oriented outside (Fig. 1). Therefore, in the
170 mixed system, the modified stationary phase will have a negative charge, although with
171 smaller density than in a system exclusively modified with SDS. Different studies have also
172 demonstrated that Brij-35 and SDS form mixed micelles in the mobile phase, with a common
173 core involving their hydrophobic chains.³⁵ Therefore, mixed micellar systems should provide
174 different chromatographic behaviour with respect to the single systems.

175 Fig. 2a shows the changes in retention for the whole set of TCAs and the two most apolar
176 β -blockers eluted with a mobile phase containing 0.02 M Brij-35 and increasing
177 concentrations of SDS in the 0.02–0.15 M range. As observed, the trends are similar for
178 TCAs and β -blockers. It can be observed that the retention factors increased dramatically with
179 the first addition of SDS. This is mainly due to the strong electrostatic attraction of the basic
180 compounds (positively charged) to the anionic SDS monomers adsorbed on the stationary

181 phase. Further addition of SDS reduces the retention, due to the increase in micelle
182 concentration which attracts the cationic solutes towards the mobile phase.

183 Fig. 2b depicts the changes in retention by adding increasing concentration of Brij-35 into
184 a 0.15 M SDS mobile phase. The retention of TCAs and β -blockers in the absence of Brij-35
185 was excessively large (often above 80 min) and could not be measured. However, the addition
186 of a small amount of Brij-35 (0.01 M) decreased the retention factors to practical analysis
187 times. Successive additions of the non-ionic surfactant gradually reduced the retention,
188 although in a smaller extent than the addition of SDS to a mobile phase containing a fixed
189 amount of Brij-35.

190 When TCAs and β -blockers are eluted with SDS mobile phases, the addition of a
191 relatively high amount of organic solvent (such as acetonitrile, propanol, butanol or pentanol),
192 or the use of a column with a shorter alkyl-bonded chain (e.g., a C8 column) is required to
193 decrease the retention times to practical values (Fig. 3a, and Fig. 4b and c).²³⁻²⁶ Thus, it was
194 checked that using a C18 column, the retention times of propranolol and alprenolol (not
195 shown) were above 120 and 30 min with SDS mobile phases in the presence of 10 and 45%
196 acetonitrile, respectively.

197 The retention times were smaller with mobile phases containing exclusively Brij-35. The
198 apolar TCAs (with octanol-water partition coefficients, $\log P_{o/w}$, ranging between 3.9 and
199 5.3)³⁶ eluted at practical retention times in these conditions (Fig. 3b). However, the retention
200 of most β -blockers (with $\log P_{o/w}$ between 0.25 and 3.4)³⁶ was excessively low. Thus, for
201 example, the retention times for oxprenolol and propranolol ($\log P_{o/w} = 2.4$ and 3.4,
202 respectively) with a mobile phase containing a small concentration of Brij-35 (0.01 M) were
203 2.7 and 11.8 min, respectively, and other more polar β -blockers eluted close to the dead time.
204 Also, the retention of the most retained β -blockers decreased significantly with 0.02 M
205 Brij-35.

206 The retention capability of the C18 stationary phase simultaneously modified with both
207 Brij-35 and SDS, towards basic compounds (such as TCAs and β -blockers), is larger
208 compared to a stationary phase exclusively modified with Brij-35, and significantly smaller
209 with regard to a stationary phase exclusively modified with SDS. The increased retention with
210 the mixed Brij-35/SDS system is not advantageous for TCAs (compare Figs. 3b and c), but
211 for β -blockers, it allows modulating the retention to practical values (Fig. 4d), without the
212 requirement of adding an organic solvent.

213

214 3.2. Solute-stationary phase and solute-mobile phase interactions

215 In the early development of MLC, a three-phase model (stationary phase, water and
216 micelle) was proposed to understand the mechanism of retention. This model gave rise to
217 equations that describe the changes in solute retention at increasing concentration of the
218 modifiers (surfactant and organic solvent).^{37,38} The approach is valid for both ionic and
219 non-ionic surfactants and considers two association equilibria between solute and stationary
220 phase, and solute and micelle. The equation proposed by Arunyanart and Cline-Love is
221 particularly useful. The following chemical equilibria are considered.³⁸



224 which describe the association of a solute (A) in bulk water with the stationary phase binding
225 sites (S), and with the surfactant monomers in the micelles dissolved in the mobile phase (M).
226 The equilibria in Eqs. (1) and (2) are described by the association constants K_{WS} and K_{AM} ,
227 respectively. The retention factor, k , can be expressed by:

$$228 k = \phi \frac{[\text{AS}]}{[\text{A}] + [\text{AM}]} = \frac{\phi K_{\text{WS}} [\text{S}]}{1 + K_{\text{AM}} [\text{M}]} = \frac{K_{\text{AS}}}{1 + K_{\text{AM}} [\text{M}]} \quad (3)$$

229 where ϕ is the phase ratio (ratio between the stationary phase and mobile phase volumes),
230 $[AS]$ and $[AM]$ are the solute concentrations associated to the stationary phase and mobile
231 phase, respectively, $[S]$ is the concentration of active sites on the stationary phase, and $[M]$ the
232 molar concentration of surfactant monomers in the mobile phase. Since $[S]$ is constant
233 (or practically constant), and assuming the column is saturated with surfactant, the product
234 $\phi K_{WS}[S]$ is also constant (K_{AS}). Eq. (3) can be rewritten as:

$$235 \quad \frac{1}{k} = \frac{1}{K_{AS}} + \frac{K_{AM}}{K_{AS}}[M] \quad (4)$$

236 which describes a $1/k$ versus surfactant concentration linear plot. The extrapolation of the
237 linear segments give a measurement of the strength of the interaction between the solute and
238 stationary phase (K_{AS}), expressed as the inverse of the intercept. The slope combined with the
239 value of K_{AS} indicates the interaction between the solute and mobile phase (K_{AM}).

240 To our knowledge, Eq. (4) has not been applied to measure the strength of the interaction
241 of solutes with stationary phases modified by the simultaneous adsorption of two surfactants
242 in the presence of mixed micelles. Both Brij-35 and SDS in the mixed micellar system
243 experience similar equilibria to those described by Eqs. (1) and (2). This allows the fitting to
244 Eq. (4) of the data obtained at increasing concentration of SDS, in the presence of fixed
245 Brij-35, and similarly, at increasing concentration of Brij-35 in the presence of fixed SDS.
246 The estimated association constants K_{AS} and K_{AM} are given in Table 1. For comparative
247 purposes, the values obtained with the micellar system containing only Brij-35 are included.
248 Owing to the strong solute-stationary phase interaction between TCAs and β -blockers with
249 the sulphate group of SDS, which yield extremely long retention times, the estimation of these
250 constants was not possible for purely micellar mobile phases of this surfactant. However,
251 based on previous work, it is known that the intercept in Eq. (4) is practically null for the
252 studied solutes eluted exclusively with SDS, indicating very high K_{AS} and K_{AM} values.^{23,24}

253 As observed in Table 1, the set of runs where SDS was increased and Brij-35 was fixed
254 yielded stronger solute-stationary phase interactions, whereas the runs where Brij-35 was
255 increased with fixed SDS provided solute affinity to the stationary phase similar or smaller
256 than that observed with the only presence of Brij-35. Thus, in a mixed Brij-35/SDS system,
257 the interaction between the basic solutes and each surfactant in the modified stationary phase
258 was different (stronger with SDS). Finally, the solute-micelle association constants (K_{AM}) in
259 the mixed micellar systems were significantly smaller. This suggests that the affinity of the
260 basic solutes to the mixed micelles is smaller, giving rise to a decreased elution strength.

261

262 3.3. Peak profiles in the mixed Brij-35/SDS micellar systems

263 The graphical representation of the left (A) and right (B) half-widths, measured at 10%
264 peak height, versus the retention time, allows an overview of the changes that occur in the
265 width and asymmetry of the chromatographic peaks obtained with a given column.
266 Measurement at 10% peak height allows the characterisation of the asymmetry without being
267 affected by the baseline noise of chromatograms. The validity of these plots to compare the
268 behaviour of different families of compounds, using different types of columns and mobile
269 phases, has been demonstrated in previous work.^{26,39-42} The construction of half-width plots is
270 very simple, being represented by the following equations:

$$271 \quad A = m_A t_R + A_0 \quad (5)$$

$$272 \quad B = m_B t_R + B_0 \quad (6)$$

273 where m_A and m_B are the slopes of the linear correlations for the left and right half-widths,
274 respectively, and A_0 and B_0 the corresponding intercepts representing the extra-column
275 contribution to the peak broadening. Eqs. (5) and (6) allow for the prediction of the peak
276 half-widths for compounds eluted at different retention times, and the calculation of the
277 apparent efficiencies associated to each compound. These parameters are also useful to

278 characterise chromatographic columns. The sum of m_A and m_B represents the broadening rate
279 of chromatographic peaks inside the column, and its ratio (m_B/m_A) indicates the peak
280 asymmetry at high retention times. The study of the effect of the surfactant mediated systems
281 on the peak profiles was performed based on the construction of plots at each mobile phase
282 composition, using the half-widths for several probe compounds eluted at that condition.

283 Fig. 5 shows the half-width plots for the TCAs and β -blockers eluted with the Brij-35
284 and/or Brij-35/SDS systems. The slopes of the linear segments for the left (m_A) and right (m_B)
285 half-widths, and its sum and ratio for the assayed mobile phases are given in Table 2. Fig. 5a
286 depicts the half-width plots for a mobile phase containing only 0.02 M Brij-35. The
287 correlations were satisfactory for both half-widths. The larger slope for the right half-width
288 indicates an appreciably peak tailing. Fig. 5b and c shows the half-width plots obtained for a
289 mixed Brij-35/SDS system. The coincidence of the slopes of the linear segments for both
290 half-widths ($m_B/m_A \approx 1.0$, which means highly symmetrical peaks) is remarkable (compare
291 with Fig. 5a). This indicates that SDS is able to protect the silanol groups in the column,
292 hindering the access of the basic compounds. Although the peak asymmetry with Brij-35
293 ($m_B/m_A = 2.33$) is significantly larger with respect to the mixed Brij-35/SDS systems, it
294 should be noted that when the basic compounds are eluted from C18 columns with aqueous-
295 organic mobile phases, the peak asymmetry may be even larger ($m_B/m_A = 3.60$, see also Fig.
296 4a).⁴²

297 The silanol masking capability of SDS has been extensively demonstrated using hybrid
298 mobile phases of SDS and organic solvent.³⁹⁻⁴² As noted, the effect is similar for the mixed
299 Brij-35/SDS system. However, m_A+m_B values are appreciably larger (i.e., the peaks are
300 broader) with respect to the mobile phases containing only Brij-35, probably due to the larger
301 carbon contents when both surfactants are adsorbed.

302

303 3.4. Selectivity and resolution

304 In order to explore the selectivity achieved with the mixed micellar systems, the retention
305 factors obtained for the TCAs, propranolol and alprenolol with a mobile phase containing
306 only Brij-35 were correlated with those using mobile phases containing both Brij-35 and SDS
307 (Fig. 6a). The retention factors for different mixed micellar mobile phases were also
308 correlated (Fig. 6b and c). The observed changes in relative retention can be explained by the
309 changes in the stationary phase nature and elution strength with the mobile phase
310 composition. Besides the significant changes in absolute retention in the presence and absence
311 of SDS, and with changes in the concentration of both surfactants, the three plots show
312 differences in selectivity. Similar results were obtained at other concentrations. We should
313 here recall that more polar β -blockers elute close to the dead time with mobile phases
314 containing only Brij-35.

315 The main goal in a chromatographic separation is to achieve the resolution of all peaks.
316 In order to observe the resolution capability of the column simultaneously modified with
317 Brij-35 and SDS, mixtures of the two sets of probe compounds (TCAs and β -blockers) were
318 eluted with mixed micellar Brij-35/SDS mobile phases. Fig. 3c shows a chromatogram
319 corresponding to the separation of several TCAs. As observed, for these compounds, mixed
320 Brij-35/SDS mobile phases do not offer any advantage with respect to the use of mobile
321 phases containing Brij-35: in the presence of SDS the peaks are significantly broader and
322 show longer retention. The TCAs remain unresolved in MLC, either with SDS/pentanol (the
323 retention times with a less polar solvent are too high), and with Brij-35 or Brij-35/SDS
324 without organic solvent. However, samples containing the individual TCAs can be analysed
325 with good results using a green RPLC method with Brij-35 in the absence of organic solvent
326 in sufficiently small analysis times. This procedure has been demonstrated to be competitive
327 against classical RPLC with an optimised mobile phase (32% acetonitrile).²⁶

328 In contrast, the mixed Brij-35/SDS system is revealed as promising to succeed in the
329 separation of mixtures of β -blockers, with a favourable effect on retention and resolution. The
330 most polar β -blockers (such as atenolol, celiprolol, metoprolol, oxprenolol, with $\log P_{o/w}$
331 values between 0.25 and 2.0), which are not sufficiently retained with mobile phases
332 containing only Brij-35, and are excessively retained with mobile phases with only SDS, are
333 eluted at practical retention times with the mixed Brij-35/SDS system. Fig. 4d depicts the
334 chromatogram for a mixture of six β -blockers, using an isocratic mobile phase containing
335 0.02 M Brij-35 and 0.15 M SDS. The mixed micellar mobile phase was able to separate the
336 set of β -blockers with an analysis time below 35 min in the absence of organic solvent.
337 A smaller analysis time will be obtained by optimising the mobile phase composition, which
338 will depend on the particular analysed β -blocker or set of β -blockers. For comparison
339 purposes, Fig. 4a shows the chromatogram of the most polar β -blockers studied in this work,
340 obtained in 15% acetonitrile. The retention of alprenolol and propranolol was above 60 min in
341 these conditions.

342 The repeatability of the retention time, and the peak efficiency and area, performing ten-
343 fold injections, are indicated in Table 3 for the six β -blockers at three concentrations. The
344 results show that the analysis can be carried out successfully with a mobile phase only
345 composed by water and two detergents at room temperature.

346

347 **4. Conclusions**

348 More than two-thirds of the reported applications in MLC employ the anionic surfactant
349 SDS, with a special relevance in the pharmaceutical field. The references on the analytical use
350 of Brij-35 in MLC are few, except in the field of QSAR studies. Although procedures using
351 the Brij-35/SDS mixture are found in the MLC literature for several types of compounds,
352 there are no previous descriptions on its application to basic compounds. Also, detailed

353 comparisons between the mixed micellar systems and those using a single surfactant
354 (as shown in this work) have not been carried out.

355 This work shows that the separation of basic compounds of diverse polarity, with
356 Brij-35/SDS mobile phases, yields retention times and peak profiles that are dominated by the
357 strong association of the cationic solutes with the adsorbed SDS on the stationary phase.
358 However, the simultaneous adsorption of Brij-35 confers the stationary phase higher polarity
359 that decreases the retention times, which are significantly shorter than those obtained with
360 mobile phases containing only SDS. This avoids the addition of organic solvent.

361 The preference for the mixed Brij-35/SDS system against the single Brij-35 system
362 depends on the polarity of the basic compounds. Thus, aqueous mobile phases containing
363 only Brij-35 are preferable to analyse apolar basic compounds (as TCAs). Meanwhile, the
364 retention of polar and moderately polar basic compounds (as β -blockers), which is too short
365 with mobile phases containing only Brij-35, can be modulated to practical values by the
366 addition of SDS to the mobile phase containing Brij-35, and may yield successful resolution.
367 Therefore, the described methods with Brij-35 in the absence or presence of SDS can be the
368 basis of successful “green” chromatographic analyses of basic compounds. The studies in this
369 work should be used as a guideline to develop the analytical procedures.

370

371 **Acknowledgements**

372 This work was supported by Project CTQ2013–42558-P (Ministry of Economy and
373 Competitiveness, Spain), and FEDER funds.

374

375

376 **References**

- 377 1 A. Berthod and M.C. García-Alvarez-Coque, *Micellar Liquid Chromatography*, Marcel
378 Dekker, New York, 2000.
- 379 2 M.J. Ruiz-Angel, M.C. García-Alvarez-Coque and A. Berthod, *Sep. Purif. Rev.*, 2009,
380 **38**, 45–96.
- 381 3 M.J. Ruiz-Angel, S. Carda-Broch, J.R. Torres-Lapasió and M.C. García-Alvarez-
382 Coque, *J. Chromatogr. A*, 2009, **1216**, 1798–1814.
- 383 4 E. Bonet-Domingo, M.J. Medina-Hernández and M.C. García-Alvarez-Coque, *Quím.*
384 *Anal.*, 1993, **12**, 167–172.
- 385 5 M.C. García-Alvarez-Coque and S. Carda-Broch, *J. Chromatogr. B*, 1999, **736**, 1–18.
- 386 6 Li Zhu, Li Ding, Qianli Zhang, Lin Wang, Fei Tang, Qian Liu and Shouzhuo Yao,
387 *Green Chemistry*, 2009, **11**, 132–137.
- 388 7 M.F. Borgerding and W.L. Hinze, *Anal. Chem.*, 1985, **57**, 2183–2190.
- 389 8 M.F. Borgerding, F.H. Quina, W.L. Hinze, J. Bowermaster and H.M. McNair, *Anal.*
390 *Chem.*, 1988, **60**, 2520–2527.
- 391 9 M.F. Borgerding, W.L. Hinze, L.D. Stafford, G.W. Fulp Jr. and W.C. Hamlin Jr., *Anal.*
392 *Chem.*, 1989, **61**, 1353–1358.
- 393 10 L.J. Cline-Love and J.J. Fett, *J. Pharm. Biomed. Anal.*, 1991, **9**, 323–333.
- 394 11 M.L. Marina, O. Jiménez, M.A. García and S. Vera, *Microchem. J.*, 1996, **53**, 215–224.
- 395 12 P. Menéndez-Fraga, A. Blanco-González, A. Sanz-Medel and J.B. Cannata-Andia,
396 *Talanta*, 1997, **45**, 25–33.
- 397 13 A. Berthod, S. Tomer and J.G. Dorsey, *Talanta*, 2001, **55**, 69–83.
- 398 14 M. Gil-Agustí, L. Alvarez-Rodríguez, L. Monferrer-Pons, D. Bose, A. Durgbanshi and
399 J. Esteve-Romero, *Anal. Lett.*, 2002, **35**, 1721–1734.
- 400 15 N. Memon, M.I. Bhangar and M.Y. Khuhawer, *J. Sep. Sci.*, 2005, **28**, 635–638.
- 401 16 W. Thogchai and B. Liawruangrath, *Int. J. Cosmetic Sci.*, 2013, **35**, 257–263.

- 402 17 Y.M. Dong, N. Li, Q. An and N.W. Lu, *J. Liq. Chromatogr., Rel. Technol.*, 2015, **38**,
403 251–258.
- 404 18 J.M. Sanchis-Mallols, R.M. Villanueva-Camañas, S. Sagrado and M.J. Medina-
405 Hernández, *Chromatographia*, 1997, **46**, 605–612.
- 406 19 C.R. Yin, L.Y. Ma, J.G. Huang, L. Xu, Z.G. Shi, *Anal. Chim. Acta*, 2013, **804**, 321–327.
- 407 20 J. Nawrocki, *J. Chromatogr. A*, 1997, **779**, 29–71.
- 408 21 S. Bocian, B. Buszewski, *J. Sep. Sci.*, 2012, **35**, 1191–1200.
- 409 22 B.K. Lavine, S. Hendayan, W.T. Cooper and Y. He, *ACS Symp. Ser.*, 2000, **740**, 290–
410 313.
- 411 23 M.J. Ruiz-Angel, J.R. Torres-Lapasió, M.C. García-Alvarez-Coque and S. Carda-
412 Broch, *Anal. Chem.*, 2008, **80**, 9705–9713.
- 413 24 M.J. Ruiz-Angel, S. Carda-Broch and M.C. García-Alvarez-Coque, *J. Chromatogr. A*,
414 2010, **1217**, 7082–7089.
- 415 25 M.J. Ruiz-Angel, S. Carda-Broch, E.F. Simó-Alfonso and M.C. García-Alvarez-Coque,
416 *J. Pharm. Biomed. Anal.*, 2003, **32**, 71–84.
- 417 26 J.J. Fernández-Navarro, M.J. Ruiz-Angel and M.C. García-Alvarez-Coque, *J. Sep. Sci.*,
418 2012, **35**, 1303–1309.
- 419 27 J.J. Baeza-Baeza, Y. Dávila, J.J. Fernández-Navarro and M.C. García-Alvarez-Coque,
420 *Anal. Bioanal. Chem.*, 2012, **404**, 2973–2984.
- 421 28 K. Ogino, H. Uchiyama and M. Abe, *Mixed Surfactant Systems*, Marcel Dekker, New
422 York, 1993.
- 423 29 X. Li and J.S. Fritz, *Anal. Chem.*, 1996, **68**, 4481–4488.
- 424 30 P. Ebrahimi and M.R. Hadjmohammadi, *Anal. Bioanal. Chem.*, 2006, **384**, 851–858.
- 425 31 J. Sun, J. Mao, X. Liu, Y. Wang, Y. Sun and Z. He, *J. Sep. Sci.*, 2009, **32**, 2043–2050.
- 426 32 R. Nakao and C. Haldin, *J. Chromatogr. A*, 2013, **1281**, 54–59.
- 427 33 O.R.T. Thomas and G.F. White, *Biotechnol. Appl. Biochem.*, 1989, **11**, 318–327.
- 428 34 M.T. Scott and M.N. Jones, *Biochim. Biophys. Acta.*, 2000, **1508**, 235–251.

- 429 35 H. Gao, S. Zhao, S. Mao, H. Yuan, J. Yu, L. Shen and Y. Du, *J. Coll. Int. Sci.*, 2002,
430 **249**, 200–208.
- 431 36 C.J. Drayton (Ed.), *Comprehensive Medicine Chemistry*, Vol. 6, Pergamon Press,
432 Oxford, 1990.
- 433 37 D.W. Armstrong and F. Nome, *Anal. Chem.*, 1981, **53**, 1662–1666.
- 434 38 M. Arunyanart and L.J. Cline-Love, *Anal. Chem.*, 1984, **56**, 1557–1561.
- 435 39 M.J. Ruiz-Angel, S. Carda-Broch and M.C. García-Alvarez-Coque, *J. Chromatogr. A*,
436 2010, **1217**, 1786–1798.
- 437 40 J.J. Fernández-Navarro, M.C. García-Alvarez-Coque and M.J. Ruiz-Angel,
438 *J. Chromatogr. A*, 2011, **1218**, 398–407.
- 439 41 S. Pous-Torres, M.J. Ruiz-Angel, J.R. Torres-Lapasió and M.C. García-Alvarez-Coque,
440 *J. Sep. Sci.*, 2009, **32**, 2841–2853.
- 441 42 M.J. Ruiz-Angel, S. Pous-Torres, S. Carda-Broch and M.C. García-Alvarez-Coque,
442 *J. Chromatogr. A*, 2014, **1344**, 76–82.
- 443

444 **FIGURE CAPTIONS**

445 **Fig. 1.** Simplified scheme of the environment of cationic solutes in a C18 stationary phase, in
446 the presence of Brij-35 and SDS.


447 **Fig. 2.** Effect of the addition of increasing concentrations of surfactant on the retention of
448 TCAs and β -blockers in a mobile phase containing a fixed concentration of a second
449 surfactant: (a) 0.02 M Brij-35 and increasing concentrations of SDS, and (b) 0.15 M SDS and
450 increasing concentrations of Brij-35. Compound identity: (+) alprenolol, (\diamond) propranolol,
451 (\square) amitriptyline, (\blacksquare) clomipramine, (\triangle) doxepin, (\blacktriangle) imipramine, (\times) maprotiline,
452 (\blacklozenge) nortriptyline, and (\blacktriangleright) trimipramine.



453 **Fig. 3.** Chromatograms for a mixture of TCAs eluted with: (a) 0.10 M SDS and 3.4% v/v
454 pentanol (Eclipse XDB C8 column), (b) 0.02 M Brij-35 (Zorbax Eclipse C18), and (c) mixed
455 micellar system composed of 0.02 M Brij-35 and 0.15 M SDS (Zorbax Eclipse C18).
456 Compound identity: (1) doxepin, (2) imipramine, (3) amitriptyline, (4) trimipramine,
457 (5) nortriptyline, and (6) clomipramine.


458 **Fig. 4.** Chromatograms for a mixture of β -blockers, eluted with: (a) 15% v/v acetonitrile
459 (Kromasil C18), (b) 0.1125 M SDS and 10% v/v acetonitrile (Kromasil C18), (c) 0.1125 M
460 SDS and 45% v/v acetonitrile (Kromasil C18), and (d) mixed micellar system composed of
461 0.02 M Brij-35 and 0.15 M SDS (Zorbax Eclipse C18). Compound identity: (1) atenolol,
462 (2) celiprolol, (3) metoprolol, (4) oxprenolol, (5) propranolol, and (6) alprenolol.

463 **Fig. 5.** Half-width plots for mobile phases containing: (a) 0.02 M Brij-35, (b,c) 0.02 M
464 Brij-35/0.15 M SDS. Left (*A*, \circ) and right (*B*, \bullet) half-widths. Compounds: (a,b) TCAs,
465 propranolol and alprenolol, and (c) atenolol, celiprolol, metoprolol and oxprenolol.

466 **Fig. 6.** Comparison of the selectivity of chromatographic systems containing only Brij-35,
467 and both Brij-35 and SDS (retention factors are plotted). The data correspond to the seven
468 TCAs, propranolol and alprenolol.











Figure 4






Table 1. Solute-stationary phase (K_{AS}) and solute-mobile phase (K_{AM}) association constants for the studied basic compounds eluted with mobile phases containing Brij-35 or mixtures of Brij-35 and SDS.

Compound	Brij-35 ^a		Brij-35 0.02 M / SDS ^b		SDS 0.15 M / Brij-35 ^a	
	K_{AS}	K_{AM}	K_{AS}	K_{AM}	K_{AS}	K_{AM}
Alprenolol	–	–	138.9	34.0	39.1	32.4
Propranolol	–	–	108.7	36.1	30.0	34.3
Amitryptiline	35.7	148.9	185.2	50.7	30.7	18.7
Clomipramine	98.0	306.5	303.0	68.2	37.7	17.5
Doxepin	14.7	74.8	161.3	61.5	21.8	17.3
Imipramine	21.9	91.8	212.8	64.0	27.6	17.0
Maprotiline	62.9	204.6	232.6	45.7	43.7	21.6
Nortryptiline	57.5	188.9	227.3	46.9	43.7	23.7
Trimipramine	36.4	151.4	200.0	45.1	38.3	21.2

^a Increasing concentration of Brij-35 from 0.01 to 0.05 M.

^b Increasing concentration of SDS from 0.02 to 0.15 M.

Table 2. Half-width plots parameters for TCAs and β -blockers eluted with different micellar mobile phases: slopes for the left (m_A) and right (m_B) half-width plot, sum of slopes and slopes ratio.


Mobile phase	m_A	m_B	m_A+m_B	m_B/m_A
Brij-35 0.02 M ^a	0.030	0.071	0.101	2.33
Brij-35 0.02 M / SDS 0.02 M ^a	0.083	0.082	0.165	0.99
Brij-35 0.02 M / SDS 0.04 M ^a	0.098	0.100	0.198	1.02
Brij-35 0.02 M / SDS 0.08 M ^a	0.141	0.150	0.291	1.06
Brij-35 0.02 M / SDS 0.12 M ^a	0.157	0.159	0.316	1.01
Brij-35 0.02 M / SDS 0.15 M ^a	0.123	0.119	0.242	0.96
Brij-35 0.01 M / SDS 0.15 M ^a	0.207	0.213	0.420	1.03
Brij-35 0.02 M / SDS 0.15 M ^a	0.123	0.119	0.242	0.96
Brij-35 0.03 M / SDS 0.15 M ^a	0.141	0.152	0.293	1.13
Brij-35 0.04 M / SDS 0.15 M ^a	0.160	0.180	0.340	1.07
Brij-35 0.05 M / SDS 0.15 M ^a	0.127	0.139	0.266	1.10
Brij-35 0.02 M / SDS 0.15 M ^b	0.0423	0.0410	0.0833	0.97

^a TCAs, alprenolol and propranolol.

^b Atenolol, celiprolol, metoprolol and oxprenolol.

Table 3. Repeatability in retention times, area and efficiency at three different concentrations of β -blockers.

Compound	2 $\mu\text{g/mL}$			7 $\mu\text{g/mL}$			14 $\mu\text{g/mL}$		
	t_R (min)	Area	N	t_R (min)	Area	N	t_R (min)	Area	N
Atenolol	4.13 \pm 0.01	1.45 \pm 0.02	940 \pm 30	4.14 \pm 0.01	6.08 \pm 0.02	880 \pm 14	4.16 \pm 0.01	11.19 \pm 0.02	870 \pm 12
Celiprolol	7.95 \pm 0.02	1.57 \pm 0.05	910 \pm 60	8.00 \pm 0.02	4.96 \pm 0.02	865 \pm 8	8.05 \pm 0.01	9.41 \pm 0.06	840 \pm 12
Metoprolol	12.86 \pm 0.02	2.92 \pm 0.05	1450 \pm 50	12.95 \pm 0.04	9.31 \pm 0.07	1400 \pm 27	13.06 \pm 0.02	17.30 \pm 0.07	1400 \pm 9
Oxprenolol	17.71 \pm 0.05	1.37 \pm 0.07	1820 \pm 150	17.86 \pm 0.07	4.19 \pm 0.03	1900 \pm 38	18.01 \pm 0.04	7.84 \pm 0.07	1840 \pm 36
Propranolol	23.28 \pm 0.12	0.89 \pm 0.16	1130 \pm 320	23.42 \pm 0.09	3.89 \pm 0.09	1300 \pm 76	23.66 \pm 0.07	6.97 \pm 0.09	1290 \pm 45
Alprenolol	30.04 \pm 0.14	0.95 \pm 0.17	1560 \pm 470	30.26 \pm 0.11	3.04 \pm 0.10	1700 \pm 160	30.60 \pm 0.08	5.54 \pm 0.22	1700 \pm 83



Mixed micellar systems of Brij-35 and sodium dodecyl sulphate without organic solvent allow the analysis of polar and moderately polar basic compounds, giving rise to a type of more sustainable RPLC.